Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 12, 2012 - Issue 10
Submit an article Journal homepage
242
Views
15
CrossRef citations to date
0
Altmetric
Theme: Nervous System Neoplasm - Review

Primary CNS lymphoma: a clinician’s guide

Niklas Schäfer Division of Clinical Neurooncology, Department of Neurology, University Hospital of Bonn, Bonn, Germany; Division of Clinical Neurooncology, Department of Neurology, University Hospital of Bonn, Bonn, Germany
,
Martin Glas Division of Clinical Neurooncology, Department of Neurology, University Hospital of Bonn, Bonn, Germany; Institute of Reconstructive Neurobiology and Stem Cell Pathologies, Life and Brain, University of Bonn, Bonn, Germany; Division of Clinical Neurooncology, Department of Neurology, University Hospital of Bonn, Bonn, Germany; Institute of Reconstructive Neurobiology and Stem Cell Pathologies, Life and Brain, University of Bonn, Bonn, Germany
&
Ulrich Herrlinger Division of Clinical Neurooncology, Department of Neurology, University Hospital of Bonn, Bonn, Germany; Division of Clinical Neurooncology, Department of Neurology, University Hospital of Bonn, Bonn, Germany. [email protected]
Pages 1197-1206 | Published online: 09 Jan 2014

References

  • Shenkier TN, Blay JY, O’Neill BP et al. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J. Clin. Oncol. 23(10), 2233–2239 (2005).
  • Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit. Rev. Oncol. Hematol. 56(1), 155–167 (2005).
  • Cavaliere R, Petroni G, Lopes MB, Schiff D; International Primary Central Nervous System Lymphoma Collaborative Group. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer 116(4), 863–870 (2010).
  • Herrlinger U, Schabet M, Bitzer M, Petersen D, Krauseneck P. Primary central nervous system lymphoma: from clinical presentation to diagnosis. J. Neurooncol. 43(3), 219–226 (1999).
  • Küker W, Nägele T, Korfel A et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J. Neurooncol. 72(2), 169–177 (2005a).
  • Fischer L, Martus P, Weller M et al. Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology 71(14), 1102–1108 (2008).
  • Whitcup SM, de Smet MD, Rubin BI et al. Intraocular lymphoma. Clinical and histopathologic diagnosis. Ophthalmology 100(9), 1399–1406 (1993).
  • Herrlinger U, Küker W, Uhl M et al.; Neuro-Oncology Working Group of the German Society. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann. Neurol. 57(6), 843–847 (2005).
  • Lachenmayer ML, Blasius E, Niehusmann P et al. Non-enhancing primary CNS lymphoma. J. Neurooncol. 101(2), 343–344 (2011).
  • Hegde U, Filie A, Little RF et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 105(2), 496–502 (2005).
  • Rhodes CH, Glantz MJ, Glantz L et al. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer 77(3), 543–548 (1996).
  • Storch-Hagenlocher B, Haas J, Vogt-Schaden ME et al. Molecular analysis of the CDR3 encoding region of the immunoglobulin heavy chain locus in cerebrospinal fluid cells as a diagnostic tool in lymphomatous meningitis. Ann. Neurol. 47(2), 211–217 (2000).
  • Gleissner B, Siehl J, Korfel A, Reinhardt R, Thiel E. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 58(3), 390–396 (2002).
  • Baraniskin A, Kuhnhenn J, Schlegel U et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 117(11), 3140–3146 (2011).
  • Herrlinger U, Schabet M, Eichhorn M et al. Prolonged corticosteroid-induced remission in primary central nervous system lymphoma: report of a case and review of the literature. Eur. Neurol. 36(4), 241–243 (1996).
  • Porter AB, Giannini C, Kaufmann T et al. Primary central nervous system lymphoma can be histologically diagnosed after previous corticosteroid use: a pilot study to determine whether corticosteroids prevent the diagnosis of primary central nervous system lymphoma. Ann. Neurol. 63(5), 662–667 (2008).
  • Forsyth PA, Yahalom J, DeAngelis LM. Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology 44(8), 1473–1479 (1994).
  • Abrey LE, Batchelor TT, Ferreri AJ et al. ; International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J. Clin. Oncol. 23(22), 5034–5043 (2005).
  • Jahnke K, Hummel M, Korfel A et al. Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J. Clin. Oncol. 24(29), 4754–4757 (2006b).
  • Mohile NA, Deangelis LM, Abrey LE. Utility of brain FDG-PET in primary CNS lymphoma. Clin. Adv. Hematol. Oncol. 6(11), 818–820, 840 (2008).
  • Küker W, Nägele T, Thiel E, Weller M, Herrlinger U. Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. Neurology 65(7), 1129–1131 (2005b).
  • Reni M, Ferreri AJ, Garancini MP, Villa E. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann. Oncol. 8(3), 227–234 (1997).
  • Nelson DF, Martz KL, Bonner H et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int. J. Radiat. Oncol. Biol. Phys. 23(1), 9–17 (1992).
  • Ferreri AJ, Blay JY, Reni M et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J. Clin. Oncol. 21(2), 266–272 (2003).
  • Abrey LE, Ben-Porat L, Panageas KS et al. Primary central nervous system lymphoma: the Memorial Sloan–Kettering Cancer Center prognostic model. J. Clin. Oncol. 24(36), 5711–5715 (2006).
  • Jahnke K, Korfel A, O’Neill BP et al. International study on low-grade primary central nervous system lymphoma. Ann. Neurol. 59(5), 755–762 (2006a).
  • Levy O, Deangelis LM, Filippa DA, Panageas KS, Abrey LE. Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer 112(1), 151–156 (2008).
  • Rubenstein JL, Fridlyand J, Shen A et al. Gene expression and angiotropism in primary CNS lymphoma. Blood 107(9), 3716–3723 (2006).
  • Hottinger AF, Iwamoto FM, Karimi S et al. YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. Ann. Neurol. 70(1), 163–169 (2011).
  • McGowan JP, Shah S. Long-term remission of AIDS-related primary central nervous system lymphoma associated with highly active antiretroviral therapy. AIDS 12(8), 952–954 (1998).
  • Raez L, Cabral L, Cai JP et al. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res. Hum. Retroviruses 15(8), 713–719 (1999).
  • Mead GM, Bleehen NM, Gregor A et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 89(6), 1359–1370 (2000).
  • Lai R, Rosenblum MK, DeAngelis LM. Primary CNS lymphoma: a whole-brain disease? Neurology 59(10), 1557–1562 (2002).
  • Angelov L, Doolittle ND, Kraemer DF et al. Blood–brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J. Clin. Oncol. 27(21), 3503–3509 (2009).
  • Ng S, Rosenthal MA, Ashley D, Cher L. High-dose methotrexate for primary CNS lymphoma in the elderly. Neuro-oncology 2(1), 40–44 (2000).
  • Jahnke K, Korfel A, Martus P et al. ; German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG). High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann. Oncol. 16(3), 445–449 (2005).
  • Zhu JJ, Gerstner ER, Engler DA et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro-oncology 11(2), 211–215 (2009).
  • Ferreri AJ, Guerra E, Regazzi M et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br. J. Cancer 90(2), 353–358 (2004).
  • Morris PG, Abrey LE, Reiner AS et al. Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. Leuk. Lymphoma 52(10), 1891–1897 (2011).
  • Joerger M, Huitema AD, Krähenbühl S et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trial. Br. J. Cancer 102(4), 673–677 (2010).
  • Joerger M, Ferreri AJ, Krähenbühl S et al. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high-dose methotrexate. Br. J. Clin. Pharmacol. 73(2), 240–247 (2012).
  • Guha-Thakurta N, Damek D, Pollack C, Hochberg FH. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J. Neurooncol. 43(3), 259–268 (1999).
  • Herrlinger U, Schabet M, Brugger W et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann. Neurol. 51(2), 247–252 (2002).
  • Batchelor T, Carson K, O’Neill A et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J. Clin. Oncol. 21(6), 1044–1049 (2003).
  • Cobert J, Hochberg E, Woldenberg N, Hochberg F. Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort. J. Neurooncol. 98(3), 385–393 (2010).
  • Thiel E, Korfel A, Martus P et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a Phase 3, randomised, non-inferiority trial. Lancet Oncol. 11(11), 1036–1047 (2010).
  • Ferreri AJ, Reni M, Foppoli M et al. ; International Extranodal Lymphoma Study Group (IELSG). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised Phase 2 trial. Lancet 374(9700), 1512–1520 (2009).
  • Pels H, Schmidt-Wolf IG, Glasmacher A et al. Primary central nervous system lymphoma: results of a pilot and Phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J. Clin. Oncol. 21(24), 4489–4495 (2003).
  • Juergens A, Pels H, Rogowski S et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann. Neurol. 67(2), 182–189 (2010).
  • Pels H, Juergens A, Schirgens I et al. Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma. Neuro-oncology 12(7), 720–724 (2010).
  • Pels H, Juergens A, Glasmacher A et al. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a Phase II study. J. Neurooncol. 91(3), 299–305 (2009).
  • McAllister LD, Doolittle ND, Guastadisegni PE et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46(1), 51–60; discussion 60 (2000).
  • Batchelor T, Grossman S, Carson K, Fisher J. Updated results from NABTT CNS consortium studies in primary CNS lymphoma. Ann. Oncol. 16, v125 (2005).
  • Abrey LE, Moskowitz CH, Mason WP et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J. Clin. Oncol. 21(22), 4151–4156 (2003).
  • Illerhaus G, Marks R, Ihorst G et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J. Clin. Oncol. 24(24), 3865–3870 (2006).
  • Illerhaus G, Müller F, Feuerhake F, Schäfer AO, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 93(1), 147–148 (2008).
  • Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J. Clin. Oncol. 18(17), 3144–3150 (2000).
  • Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J. Clin. Oncol. 24(28), 4570–4574 (2006).
  • Shah GD, Yahalom J, Correa DD et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J. Clin. Oncol. 25(30), 4730–4735 (2007).
  • Ekenel M, Iwamoto FM, Ben-Porat LS et al. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. Cancer 113(5), 1025–1031 (2008).
  • Gerard LM, Imrie KR, Mangel J et al. High-dose methotrexate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphoma. Leuk. Lymphoma 52(10), 1882–1890 (2011).
  • Fritsch K, Kasenda B, Hader C et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann. Oncol. 22(9), 2080–2085 (2011).
  • Illerhaus G, Marks R, Müller F et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and Phase II study. Ann. Oncol. 20(2), 319–325 (2009).
  • Ney DE, Reiner AS, Panageas KS, Brown HS, DeAngelis LM, Abrey LE. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan–Kettering Cancer Center experience. Cancer 116(19), 4605–4612 (2010).
  • Omuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J. Neurooncol. 85(2), 207–211 (2007).
  • Correa DD, DeAngelis LM, Shi W, Thaler H, Glass A, Abrey LE. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62(4), 548–555 (2004).
  • Harder H, Holtel H, Bromberg JE et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62(4), 544–547 (2004).
  • Correa DD, Shi W, Abrey LE et al. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro-oncology 14(1), 101–108 (2012).
  • Chamberlain MC, Levin VA. Primary central nervous system lymphoma: a role for adjuvant chemotherapy. J. Neurooncol. 14(3), 271–275 (1992).
  • Kurzwelly D, Glas M, Roth P et al. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J. Neurooncol. 97(3), 389–392 (2010).
  • Nelson DF. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J. Neurooncol. 43(3), 241–247 (1999).
  • Bataille B, Delwail V, Menet E et al. Primary intracerebral malignant lymphoma: report of 248 cases. J. Neurosurg. 92(2), 261–266 (2000).
  • Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J. Clin. Oncol. 16(3), 859–863 (1998).
  • Herrlinger U, Schabet M, Brugger W et al. Primary central nervous system lymphoma 1991–1997: outcome and late adverse effects after combined modality treatment. Cancer 91(1), 130–135 (2001).
  • Bessell EM, Graus F, López-Guillermo A et al. CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin’s lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 50(2), 457–464 (2001).
  • Omuro A, Taillandier L, Chinot O et al. ; ANOCEF Group (French Neuro-Oncology Association). Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred? J. Neurooncol. 104(1), 323–330 (2011).
  • Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J. Clin. Oncol. 23(7), 1507–1513 (2005).
  • Hormigo A, Abrey L, Heinemann MH, DeAngelis LM. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br. J. Haematol. 126(2), 202–208 (2004).
  • Jahnke K, Thiel E, Bechrakis NE et al. Ifosfamide or trofosfamide in patients with intraocular lymphoma. J. Neurooncol. 93(2), 213–217 (2009).
  • Grimm SA, McCannel CA, Omuro AM et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology 71(17), 1355–1360 (2008).
  • Smith JR, Rosenbaum JT, Wilson DJ et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 109(9), 1709–1716 (2002).
  • Helbig H, Cerny T, de Smet MD. [Intravitreal chemotherapy for intraocular lymphoma]. Ophthalmologe 100(2), 145–149 (2003).
  • Ferreri AJ, Blay JY, Reni M et al. ; International Extranodal Lymphoma Study Group (IELSG). Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann. Oncol. 13(4), 531–538 (2002).
  • Glantz MJ, LaFollette S, Jaeckle KA et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J. Clin. Oncol. 17(10), 3110–3116 (1999).
  • Ostermann K, Pels H, Kowoll A, Kuhnhenn J, Schlegel U. Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma. J. Neurooncol. 103(3), 635–640 (2011).
  • Recht L, Straus DJ, Cirrincione C, Thaler HT, Posner JB. Central nervous system metastases from non-Hodgkin’s lymphoma: treatment and prophylaxis. Am. J. Med. 84(3 Pt 1), 425–435 (1988).
  • Rubenstein JL, Fridlyand J, Abrey L et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J. Clin. Oncol. 25(11), 1350–1356 (2007).
  • Batchelor T, Leahy N, Kaufman D. High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkin’s lymphoma. Clin. Lymphoma 2(2), 116–119; discussion 120 (2001).
  • Morra E, Lazzarino M, Brusamolino E et al. The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients. Cancer 72(2), 439–445 (1993).
  • Jacomet C, Girard PM, Lebrette MG, Farese VL, Monfort L, Rozenbaum W. Intravenous methotrexate for primary central nervous system non-Hodgkin’s lymphoma in AIDS. AIDS 11(14), 1725–1730 (1997).
  • Chamberlain MC. Long survival in patients with acquired immune deficiency syndrome-related primary central nervous system lymphoma. Cancer 73(6), 1728–1730 (1994).
  • Chamberlain MC, Kormanik PA. AIDS-related central nervous system lymphomas. J. Neurooncol. 43(3), 269–276 (1999).
  • Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J. Clin. Oncol. 27(20), 3354–3362 (2009).
  • Plotkin SR, Betensky RA, Hochberg FH et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin. Cancer Res. 10(17), 5643–5646 (2004).
  • Soussain C, Hoang-Xuan K, Taillandier L et al. ; Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J. Clin. Oncol. 26(15), 2512–2518 (2008).
  • Cheng T, Forsyth P, Chaudhry A et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant. 31(8), 679–685 (2003).
  • Reni M, Mason W, Zaja F et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a Phase II trial. Eur. J. Cancer 40(11), 1682–1688 (2004).
  • Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63(5), 901–903 (2004).
  • Wong ET, Tishler R, Barron L, Wu JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 101(1), 139–145 (2004).
  • Nayak L, Abrey LE, Drappatz J et al. Multicenter Phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) study 05-01. J. Clin. Oncol. 29, Abstract 2039 (2011).
  • Fischer L, Thiel E, Klasen HA et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann. Oncol. 17(7), 1141–1145 (2006).
  • Voloschin AD, Betensky R, Wen PY, Hochberg F, Batchelor T. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J. Neurooncol. 86(2), 211–215 (2008).
  • Boiardi A, Silvani A, Pozzi A, Salmaggi A. Radiotherapy at tumor recurrence in primary CNS lymphoma. Neurology 50(6), 1934–1935 (1998).
  • Reni M, Ferreri AJ, Villa E. Second-line treatment for primary central nervous system lymphoma. Br. J. Cancer 79(3–4), 530–534 (1999).
  • Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 69(11), 1178–1182 (2007).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.